Division of Endocrinology, University of Arizona College of Medicine, Tucson, Arizona.
Department of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada.
Am J Physiol Endocrinol Metab. 2022 Oct 1;323(4):E389-E401. doi: 10.1152/ajpendo.00078.2022. Epub 2022 Aug 24.
Although the physiological role of glucagon receptor signaling in the liver is well defined, the impact of glucagon receptor (Gcgr) signaling on white adipose tissue (WAT) continues to be debated. Although numerous studies propose that glucagon stimulates WAT lipolysis, we lack evidence that physiological concentrations of glucagon regulate WAT lipolysis. In turn, we performed studies in both wild-type and WAT knockout mice to determine if glucagon regulates lipolysis at WAT in the mouse. We assessed the effects of fasting and acute exogenous glucagon administration in wild-type C57BL/6J and versus mice. Using an ex vivo lipolysis protocol, we further examined the direct effects of glucagon on physiologically (fasted) and pharmacologically stimulated lipolysis. We found that adipocyte expression did not affect fasting-induced lipolysis or hepatic lipid accumulation in lean or diet-induced obese (DIO) mice. Acute glucagon administration did not affect serum nonesterified fatty acids (NEFA), leptin, or adiponectin concentration, but did increase serum glucose and FGF21, regardless of genotype. Glucagon did not affect ex vivo lipolysis in explants from either or mice. expression did not affect fasting-induced or isoproterenol-stimulated lipolysis from WAT explants. Moreover, glucagon receptor signaling at WAT did not affect body weight or glucose homeostasis in lean or DIO mice. Our studies have established that physiological levels of glucagon do not regulate WAT lipolysis, either directly or indirectly. Given that glucagon receptor agonism can improve dyslipidemia and decrease hepatic lipid accumulation, it is critical to understand the tissue-specific effects of glucagon receptor action. Unlike the crucial role of hepatic glucagon receptor signaling in maintaining glucose and lipid homeostasis, we observed no metabolic consequence of WAT glucagon receptor deletion. It has been postulated that glucagon stimulates lipolysis and fatty acid release from white adipose tissue. We observed no metabolic effects of eliminating or activating glucagon receptor signaling at white adipose tissue.
虽然胰高血糖素受体信号在肝脏中的生理作用已得到充分证实,但胰高血糖素受体 (Gcgr) 信号对白色脂肪组织 (WAT) 的影响仍存在争议。尽管许多研究表明胰高血糖素刺激 WAT 的脂肪分解,但我们缺乏证据表明生理浓度的胰高血糖素调节 WAT 的脂肪分解。反过来,我们在野生型和 WAT 敲除小鼠中进行了研究,以确定胰高血糖素是否调节小鼠 WAT 的脂肪分解。我们评估了禁食和急性外源性胰高血糖素给药对野生型 C57BL/6J 和 小鼠的影响。使用离体脂肪分解方案,我们进一步研究了胰高血糖素对生理(禁食)和药理学刺激脂肪分解的直接影响。我们发现,脂肪细胞 表达不影响瘦鼠或饮食诱导肥胖 (DIO) 小鼠的禁食诱导的脂肪分解或肝脂质积累。急性胰高血糖素给药不影响血清非酯化脂肪酸 (NEFA)、瘦素或脂联素浓度,但无论基因型如何,均能增加血清葡萄糖和 FGF21。胰高血糖素不影响来自 或 小鼠的离体脂肪分解。 表达不影响 WAT 脂肪分解,无论是来自禁食或异丙肾上腺素刺激的脂肪分解。此外,WAT 中的胰高血糖素受体信号不影响瘦鼠或 DIO 小鼠的体重或葡萄糖稳态。我们的研究表明,生理水平的胰高血糖素既不能直接也不能间接调节 WAT 的脂肪分解。鉴于胰高血糖素受体激动剂可以改善血脂异常并减少肝脂质积累,了解胰高血糖素受体作用的组织特异性影响至关重要。与肝脏胰高血糖素受体信号在维持葡萄糖和脂质稳态中的关键作用不同,我们观察到 WAT 胰高血糖素受体缺失没有代谢后果。有人提出,胰高血糖素刺激白色脂肪组织的脂肪分解和脂肪酸释放。我们没有观察到消除或激活白色脂肪组织胰高血糖素受体信号的代谢影响。